KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Gross Profit (2016 - 2025)

Historic Gross Profit for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $145.2 million.

  • Pacira BioSciences' Gross Profit rose 1197.22% to $145.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $567.5 million, marking a year-over-year increase of 981.8%. This contributed to the annual value of $530.5 million for FY2024, which is 820.48% up from last year.
  • As of Q3 2025, Pacira BioSciences' Gross Profit stood at $145.2 million, which was up 1197.22% from $140.2 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Gross Profit peaked at $147.4 million during Q4 2024, and registered a low of $87.7 million during Q1 2021.
  • Moreover, its 5-year median value for Gross Profit was $121.3 million (2023), whereas its average is $121.6 million.
  • Per our database at Business Quant, Pacira BioSciences' Gross Profit surged by 8861.28% in 2021 and then tumbled by 869.12% in 2023.
  • Over the past 5 years, Pacira BioSciences' Gross Profit (Quarter) stood at $120.2 million in 2021, then decreased by 8.44% to $110.0 million in 2022, then rose by 21.37% to $133.6 million in 2023, then grew by 10.34% to $147.4 million in 2024, then dropped by 1.44% to $145.2 million in 2025.
  • Its last three reported values are $145.2 million in Q3 2025, $140.2 million for Q2 2025, and $134.6 million during Q1 2025.